Skip to main content
SpringerLink
Log in

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

  • Chapter
  • First Online:
Pathogenesis and Treatment of Leukemia

  • 445 Accesses

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the standard of care (SOC) for adult acute lymphoblastic leukemia (ALL) patients. In this chapter, we will discuss the indication of allo-HSCT for ALL, donor selection, outcomes of ALL following allo-HSCT, prophylaxis, and prevention of relapse post-transplant, and impact of new immunotherapeutic agents on allo-HSCT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019;54(6):798–809. https://doi.org/10.1038/s41409-018-0373-4.

    Article  PubMed  Google Scholar 

  2. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. https://doi.org/10.1038/bcj.2017.53.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Aljurf M, Weisdorf D, Alfraih F, Szer J, Muller C, Confer D, et al. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries. Bone Marrow Transplant. 2019;54(8):1179–88. https://doi.org/10.1038/s41409-019-0476-6.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–48.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–40. https://doi.org/10.1182/blood-2015-04-639831.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, et al. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019;3(12):1826–36. https://doi.org/10.1182/bloodadvances.2019000050.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Shem-Tov N, Peczynski C, Labopin M, Itala-Remes M, Blaise D, Labussiere-Wallet H, et al. Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia. 2020;34(1):283–92. https://doi.org/10.1038/s41375-019-0544-3.

    Article  PubMed  Google Scholar 

  8. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956–62. https://doi.org/10.1182/blood-2015-02-627786.

    Article  PubMed  Google Scholar 

  9. Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22(14):3467–76. https://doi.org/10.1158/1078-0432.CCR-15-2335.

    Article  PubMed  Google Scholar 

  10. NCCN guideline :Acute lymphoblastic leukemia. Version2.2020; http://www.nccn.org.

  11. NCCN guideline : Pediatric acute lymphoblastic leukemia. Version1.2020; http://www.nccn.org.

  12. Sebban C, Lepage E, Vernant JP, Gluckman E, Attal M, Reiffers J, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1994;12(12):2580–7. https://doi.org/10.1200/JCO.1994.12.12.2580.

    Article  PubMed  Google Scholar 

  13. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489–96. https://doi.org/10.1182/blood-2009-01-199380.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Couban S, Savoie L, Mourad YA, Leber B, Minden M, Turner R, et al. Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus. Curr Oncol. 2014;21(2):e265–309. https://doi.org/10.3747/co.21.1834.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Xu L, Chen H, Chen J, Han M, Huang H, Lai Y, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018;11(1):33. https://doi.org/10.1186/s13045-018-0564-x. 10.1186/s13045-018-0564-x [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  16. Wang J, Jiang Q, Xu LP, Zhang XH, Chen H, Qin YZ, et al. Allogeneic stem cell transplantation versus tyrosine kinase inhibitors combined with chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(4):741–50. https://doi.org/10.1016/j.bbmt.2017.12.777.

    Article  PubMed  Google Scholar 

  17. Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129(5):572–81. https://doi.org/10.1182/blood-2016-07-726588.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, et al. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015;125(4):680–6. https://doi.org/10.1182/blood-2014-09-595744.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394–401. https://doi.org/10.1200/JCO.2016.69.0073.

    Article  PubMed  Google Scholar 

  20. Roberts KG, Reshmi SC, Harvey RC, Chen IM, Patel K, Stonerock E, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood. 2018;132(8):815–24. https://doi.org/10.1182/blood-2018-04-841676.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2017;130(19):2064–72. https://doi.org/10.1182/blood-2017-06-743252.

    Article  PubMed  PubMed Central  Google Scholar 

  22. El Fakih R, Savani B, Mohty M, Aljurf M. Hematopoietic cell transplant consideration for Philadelphia chromosome-like acute lymphoblastic leukemia patients. Biol Blood Marrow Transplant. 2020;26(1):e16–20. https://doi.org/10.1016/j.bbmt.2019.08.010.

    Article  PubMed  Google Scholar 

  23. Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, et al. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood. 2009;113(6):1375–82. https://doi.org/10.1182/blood-2008-07-168625.

    Article  PubMed  Google Scholar 

  24. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827–33. https://doi.org/10.1182/blood-2007-10-116582.

    Article  PubMed  Google Scholar 

  25. Yan CH, Jiang Q, Wang J, Xu LP, Liu DH, Jiang H, et al. Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant. 2014;20(9):1314–21. https://doi.org/10.1016/j.bbmt.2014.04.011.

    Article  PubMed  Google Scholar 

  26. Lv M, Jiang Q, Zhou DB, Hu Y, Liu DH, Wu DP, et al. Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. J Hematol Oncol. 2020;13(1):52. https://doi.org/10.1186/s13045-020-00879-1.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M. Swedish Adult Acute Lymphocytic Leukemia G et al. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006;107(7):1551–61. https://doi.org/10.1002/cncr.22189.

    Article  PubMed  Google Scholar 

  28. Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children’s oncology group. J Clin Oncol. 2009;27(31):5189–94. https://doi.org/10.1200/JCO.2008.20.8959.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112(5):1646–54. https://doi.org/10.1182/blood-2008-01-130237.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, et al. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016;91(3):322–9. https://doi.org/10.1002/ajh.24285.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Han LJ, Wang Y, Fan ZP, Huang F, Zhou J, Fu YW, et al. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2017;179(1):120–30. https://doi.org/10.1111/bjh.14854.

    Article  PubMed  Google Scholar 

  32. Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, et al. Haploidentical transplantation with post-transplantation cyclophosphamide for high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2017;23(2):318–24. https://doi.org/10.1016/j.bbmt.2016.11.008.

    Article  PubMed  Google Scholar 

  33. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91(8):819–23. https://doi.org/10.1002/ajh.24419.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Friend BD, Schiller GJ. Closing the gap: novel therapies in treating acute lymphoblastic leukemia in adolescents and young adults. Blood Rev. 2018;32(2):122–9. https://doi.org/10.1016/j.blre.2017.09.005.

    Article  PubMed  Google Scholar 

  35. Muffly L, Alvarez E, Lichtensztajn D, Abrahao R, Gomez SL, Keegan T. Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study. Blood Adv. 2018;2(8):895–903. https://doi.org/10.1182/bloodadvances.2017014944.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Aldoss I, Pullarkat V. Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD? Bone Marrow Transplant. 2019;54(1):3–5. https://doi.org/10.1038/s41409-018-0398-8.

    Article  PubMed  Google Scholar 

  37. Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116–23. https://doi.org/10.1182/blood-2005-07-2708.

    Article  PubMed  Google Scholar 

  38. Raff T, Gokbuget N, Luschen S, Reutzel R, Ritgen M, Irmer S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109(3):910–5. https://doi.org/10.1182/blood-2006-07-037093.

    Article  PubMed  Google Scholar 

  39. Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486–96.; quiz 586. https://doi.org/10.1182/blood-2014-09-599894.

    Article  PubMed  Google Scholar 

  40. Xu ZL, Huang XJ, Liu KY, Chen H, Zhang XH, Han W, et al. Haploidentical hematopoietic stem cell transplantation for paediatric high-risk T-cell acute lymphoblastic leukaemia. Pediatr Transplant. 2016;20(4):572–80. https://doi.org/10.1111/petr.12704.

    Article  PubMed  Google Scholar 

  41. Xue YJ, Suo P, Huang XJ, Lu AD, Wang Y, Zuo YX, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2020;188(5):757–67. https://doi.org/10.1111/bjh.16226.

    Article  PubMed  Google Scholar 

  42. Xue YJ, Cheng YF, Lu AD, Wang Y, Zuo YX, Yan CH, et al. Allogeneic hematopoietic stem cell transplantation, especially haploidentical, may improve long-term survival for high-risk pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2019;25(8):1611–20. https://doi.org/10.1016/j.bbmt.2018.12.007.

    Article  PubMed  Google Scholar 

  43. Bai L, Cheng YF, Lu AD, Suo P, Wang Y, Zuo YX, et al. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leuk Res. 2020;91:106333. https://doi.org/10.1016/j.leukres.2020.106333.

    Article  PubMed  Google Scholar 

  44. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730–8. https://doi.org/10.1200/JCO.2010.28.8852.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–50. https://doi.org/10.1182/blood-2006-05-018192.

    Article  PubMed  Google Scholar 

  46. Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, et al. Transplant outcomes for children with T cell acute lymphoblastic leukemia in second remission: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2015;21(12):2154–9. https://doi.org/10.1016/j.bbmt.2015.08.023.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Liu DH, Xu LP, Liu KY, Wang Y, Chen H, Han W, et al. Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia. Bone Marrow Transplant. 2013;48(12):1519–24. https://doi.org/10.1038/bmt.2013.99.

    Article  PubMed  Google Scholar 

  48. Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28(31):4755–61. https://doi.org/10.1200/JCO.2010.30.1325. JCO.2010.30.1325 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  49. Marks DI, Perez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008;112(2):426–34. https://doi.org/10.1182/blood-2007-12-128918. S0006-4971(20)47014-4 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  50. Chang YJ, Wang Y, Xu LP, Zhang XH, Chen H, Chen YH, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol. 2020;13(1):27. https://doi.org/10.1186/s13045-020-00860-y.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Gao L, Zhang C, Gao L, Liu Y, Su Y, Wang S, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China. J Hematol Oncol. 2015;8:90. https://doi.org/10.1186/s13045-015-0186-5.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Santoro N, Ruggeri A, Labopin M, Bacigalupo A, Ciceri F, Gulbas Z, et al. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017;10(1):113. https://doi.org/10.1186/s13045-017-0480-5.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Li SQ, Fan QZ, Xu LP, Wang Y, Zhang XH, Chen H, et al. Different effects of pre-transplantation measurable residual disease on outcomes according to transplant modality in patients with Philadelphia chromosome positive ALL. Front Oncol. 2020;10:320. https://doi.org/10.3389/fonc.2020.00320.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Wang Y, Liu QF, Wu DP, Xu LP, Liu KY, Zhang XH, et al. Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients. Br J Haematol. 2020;189(1):153–61. https://doi.org/10.1111/bjh.16303.

    Article  PubMed  Google Scholar 

  55. Zhao XS, Liu YR, Xu LP, Wang Y, Zhang XH, Chen H, et al. Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. Am J Hematol. 2019;94(5):512–21. https://doi.org/10.1002/ajh.25417.

    Article  PubMed  Google Scholar 

  56. Zhao H, Wei J, Wei G, Luo Y, Shi J, Cui Q, et al. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. J Hematol Oncol. 2020;13(1):42. https://doi.org/10.1186/s13045-020-00873-7.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socie G, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016;51(3):351–7. https://doi.org/10.1038/bmt.2015.278.

    Article  PubMed  Google Scholar 

  58. Curran E, Stock W. How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 2015;125(24):3702–10. https://doi.org/10.1182/blood-2014-11-551481.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, et al. Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(4):726–33. https://doi.org/10.1016/j.bbmt.2017.11.025.

    Article  PubMed  Google Scholar 

  60. Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, et al. Comparison of cyclophosphamide combined with total body irradiation, oral busulfan, or intravenous busulfan for allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2016;22(12):2194–200. https://doi.org/10.1016/j.bbmt.2016.09.007.

    Article  PubMed  Google Scholar 

  61. Eder S, Beohou E, Labopin M, Sanz J, Finke J, Arcese W, et al. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92(1):18–22. https://doi.org/10.1002/ajh.24567.

    Article  PubMed  Google Scholar 

  62. Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, et al. Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults. Am J Hematol. 2018;93(1):47–57. https://doi.org/10.1002/ajh.24933.

    Article  PubMed  Google Scholar 

  63. Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, et al. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. J Hematol Oncol. 2016;9(1):131. https://doi.org/10.1186/s13045-016-0357-z.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Jin X, Cao Y, Wang L, Sun R, Cheng L, He X, et al. HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation. Leukemia. 2020;34(3):909–13. https://doi.org/10.1038/s41375-019-0610-x.

    Article  PubMed  Google Scholar 

  65. Zhang C, Kong PY, Li S, Chen T, Ni X, Li Y, et al. Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed/refractory acute lymphoblastic leukemia: case report and review of the literature. J Immunother. 2018;41(6):306–11. https://doi.org/10.1097/CJI.0000000000000233.

    Article  PubMed  Google Scholar 

  66. Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019;3(4):670–80. https://doi.org/10.1182/bloodadvances.2018027003.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Piemontese S, Boumendil A, Labopin M, Schmid C, Ciceri F, Arcese W, et al. Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. J Hematol Oncol. 2019;12(1):68. https://doi.org/10.1186/s13045-019-0751-4. 10.1186/s13045-019-0751-4 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  68. Wang HT, Chang YJ, Xu LP, Liu DH, Wang Y, Liu KY, et al. EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation. Bone Marrow Transplant. 2014;49(7):927–33. https://doi.org/10.1038/bmt.2014.80. bmt201480 [pii]

    Article  PubMed  Google Scholar 

  69. Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol. 2012;5(1):29. https://doi.org/10.1186/1756-8722-5-29.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Caocci G, Vacca A, Ledda A, Murgia F, Piras E, Greco M, et al. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012;18(4):652–4. https://doi.org/10.1016/j.bbmt.2011.12.587.

    Article  PubMed  Google Scholar 

  71. Renzi D, Marchesi F, De Angelis G, Elia L, Salvatorelli E, Gumenyuk S, et al. Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant. Chemotherapy. 2017;62(1):58–61. https://doi.org/10.1159/000448750.

    Article  PubMed  Google Scholar 

  72. Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev. 2013;27(1):55–62. https://doi.org/10.1016/j.blre.2012.11.002. S0268-960X(12)00074-4 [pii]

    Article  PubMed  Google Scholar 

  73. Wang Y, Liu DH, Fan ZP, Sun J, Wu XJ, Ma X, et al. Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. Clin Transpl. 2012;26(4):635–43. https://doi.org/10.1111/j.1399-0012.2012.01626.x.

    Article  Google Scholar 

  74. Wang Y, Liu QF, Wu DP, Wang JB, Zhang X, Wang HX, et al. Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. Sci China Life Sci. 2020;63(10):1552–64. https://doi.org/10.1007/s11427-019-1610-2. 10.1007/s11427-019-1610-2 [pii]

    Article  PubMed  Google Scholar 

  75. Liu S, Luo X, Zhang X, Xu L, Wang Y, Yan C, et al. Preemptive interferon-alpha treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. Sci Rep. 2020;10(1):20148. https://doi.org/10.1038/s41598-020-77186-9. 10.1038/s41598-020-77186-9 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  76. Yan CH, Wang Y, Wang JZ, Chen YH, Chen Y, Wang FR, et al. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. J Hematol Oncol. 2016;9(1):87. https://doi.org/10.1186/s13045-016-0319-5.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Sun W, Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, et al. Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. Bone Marrow Transplant. 2019;54(8):1198–207. https://doi.org/10.1038/s41409-018-0406-z. 10.1038/s41409-018-0406-z [pii]

    Article  PubMed  Google Scholar 

  78. Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–8. https://doi.org/10.1038/nm.4441. nm.4441 [pii]

    Article  PubMed  Google Scholar 

  79. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28. https://doi.org/10.1016/S0140-6736(14)61403-3. doi:S0140-6736(14)61403-3 [pii]

    Article  PubMed  Google Scholar 

  80. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. https://doi.org/10.1056/NEJMoa1407222.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48. https://doi.org/10.1056/NEJMoa1709866.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113–22. https://doi.org/10.1002/ajh.25582.

    Article  PubMed  Google Scholar 

  83. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38. https://doi.org/10.1172/JCI85309. 85309 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  84. Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652–63. https://doi.org/10.1182/blood-2018-11-883710. S0006-4971(20)42636-9 [pii]

    Article  PubMed  PubMed Central  Google Scholar 

  85. Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017;179(4):598–605. https://doi.org/10.1111/bjh.14923.

    Article  PubMed  Google Scholar 

  86. Chen YH, Zhang X, Cheng YF, Chen H, Mo XD, Yan CH, et al. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2020;22(12):755–61. https://doi.org/10.1016/j.jcyt.2020.08.002. doi:S1465-3249(20)30814-8 [pii]

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing, China

    Meng Lv, Wei Sun & Xiao-Jun Huang

Authors
  1. Meng Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-Jun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao-Jun Huang .

Editor information

Editors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Harinder Gill

  2. Department of Medicine, Queen Mary Hospital, Hongkong, Hong Kong

    Yok-Lam Kwong

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lv, M., Sun, W., Huang, XJ. (2023). Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. In: Gill, H., Kwong, YL. (eds) Pathogenesis and Treatment of Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-99-3810-0_24

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-3810-0_24

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-3809-4

  • Online ISBN: 978-981-99-3810-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation